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Modelling the effect of beliefs about asthma medication and
treatment intrusiveness on adherence and preference for once-
daily vs. twice-daily medication
Sarah Chapman1, Peter Dale2,7, Henrik Svedsater2, Gillian Stynes2,6, Nicola Vyas3, David Price 4 and Rob Horne5
People with asthma who do not adhere to their maintenance medication may experience poorer asthma control and need more
healthcare support than those who adhere. People (N = 1010) aged 18–55 years with self-reported asthma, taking one or more
asthma maintenance medication(s), from ﬁve European countries, participated in a survey using validated scales (Medication
Adherence Report Scale [MARS], Asthma Control Test™ [ACT], Beliefs about Medicine Questionnaire [BMQ] and the Asthma
Treatment Intrusiveness Questionnaire [ATIQ]). We performed a post hoc evaluation of adherence to maintenance medication,
asthma control, beliefs about medication, preferences for once-daily vs. twice-daily asthma maintenance medication and treatment
intrusiveness, using structural equation modelling to investigate the relationships between these factors. Most participants
reported potential problems with asthma control (ACT < 19: 76.8% [n = 776]), low adherence (median MARS = 3.40) and preferred
once-daily medication (73.5% [n = 742/1010]). Non-adherence was associated with worse asthma control (r = 0.262 [P < 0.001]) and
a expressed preference for once-daily medication over a "twice daily medication that works slightly better" (test statistic [T] = 2.970
[P = 0.003]). Participants reporting non-adherence/preferring once-daily medication had negative beliefs about their treatment
(BMQ necessity-concerns differential: r = 0.437 [P < 0.001]/T = 6.886 [P < 0.001]) and found medication intrusive (ATIQ: r = −0.422 [P
< 0.001]/T = 2.689[P = 0.007]). Structural equation modelling showed complex relationships between variables, including: (1) high
concerns about treatment associated with increased perceived treatment intrusiveness and reduced adherence, which inﬂuenced
asthma control; (2) high concerns about treatment and healthcare seeking behaviour, which were predictive of preferring twice-
daily asthma medication. Concerns about medication and perceived treatment intrusiveness were predictive of poor adherence,
and were associated with preference for once-daily asthma medication. Conﬁrm the utility of the PAPA model and NCF in
explaining nonadherence linked to poor asthma control.
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INTRODUCTION
Asthma is a common chronic condition, with an estimated global
prevalence of 4.3–4.5%, with higher rates (5.3%) reported in
urbanised regions, such as in Europe.1 Approximately 1 in 250
deaths globally are attributed to asthma,2 and the condition places
a signiﬁcant burden on patients, their families, healthcare systems
and the economy, including morbidity, absenteeism and pre-
senteeism, hospitalisation, reduced quality of life and costs.3,4
Despite a wide range of treatment options, many people
continue to experience uncontrolled asthma, increasing the risk of
morbidity, mortality and poor quality of life.5 While treatments do
not effectively control symptoms in some people with asthma
(who continue to experience exacerbations despite taking therapy
as prescribed), many do not take their medication as prescribed
(non-adherence)6 and consequently do not experience the full
beneﬁt from treatment. Non-adherence rates of 35–86% have
been reported in people with asthma.7,8 Non-adherence includes
several different types of behaviour, such as failure to initiate
therapy, failure to take medication as instructed (implementation,
which may result from having poor inhaler technique) and lack of
persistence in continuing therapy as directed.9,10 Typically, non-
adherence is examined as the latter two, which are possible to
measure following treatment prescription.
It is important to identify people with asthma who are at risk of
non-adherence, as non-adherence can be predictive of poor
asthma control11 and adverse clinical outcomes, such as asthma
exacerbations.12–14 Furthermore, understanding the reasons for
non-adherence and identifying people who would prefer to
switch to a once-daily treatment may aid physicians in prescribing
the most appropriate treatment and thus maximise adherence.
Medication adherence is best understood as the product of two
overlapping constructs: motivation and ability.15 Beliefs about
treatment are important. Adherence is inﬂuenced by the patient’s
evaluation of their treatment, particularly how they judge
the necessity for the treatment relative to their concerns about
the (actual and potential) adverse consequences of using it. The
Necessity–Concerns Framework (NCF) includes these two aspects
of patients’ perceptions that inﬂuence adherence,16 and the
Received: 23 June 2017 Revised: 26 September 2017 Accepted: 13 October 2017
1University of Bath, Bath, UK; 2GSK, Brentford, UK; 3Healthcare Research Worldwide, Wallingford Oxon, UK; 4Observational and Pragmatic Research Institute, Singapore, Singapore
and 5University College London, London, UK
Correspondence: Rob Horne (r.horne@ucl.ac.uk)
6Present address: Gillian Stynes, Bristol-Myers Squibb, Uxbridge, UK
7Present address: Peter Dale, HEOR Solutions Ltd, Marlow, UK
www.nature.com/npjpcrm
Published in partnership with Primary Care Respiratory Society UK
Beliefs about Medicines Questionnaire (BMQ) provides a brief,
valid and reliable method for measuring these beliefs.17 Studies
applying these approaches to maintenance treatment in asthma
show that non-adherence is related to patients’ doubts about their
personal need (necessity beliefs) and concerns.16,18–22 These
beliefs may arise in part from how patients perceive their
treatment experiences; for example, someone with asthma who
is asymptomatic may not detect a change in symptoms from their
asthma maintenance medication, potentially reinforcing a belief
that they do not need to take it.23
The importance of patients’ beliefs about illness and treatment is
recognised by the National Institute for Clinical Excellence medicines
adherence guidelines (NICE),24 which takes a perceptions and
practicalities approach (PAPA),15,25 advocating that adherence
support should focus on perceptions (e.g., our beliefs about, and
experiences of, the illness and treatment) as well as practicalities
(e.g., capacity, resources and access to treatment) in order to follow
the treatment recommendations. A key practical issue is the
complexity of treatment regimens,26 and simplifying the regimen
may be an example of an incentive to facilitate adherence.
Once-daily asthma maintenance medication regimens may
reduce the burden of treatment, compared with more frequently
required therapy, and thus improve adherence.27–29 However, the
evidence for patient preference for, and adherence to, once-daily
treatments remains limited. The PAPA may be useful to explore
preference for once-daily treatments because identiﬁcation of
practical barriers to adherence for a patient’s current asthma
treatment regimen may predict whether they wish to switch to a
once-daily medication. In asthma, good control and low self-
perceived controller medication need have been associated with
once-daily medication preference.30
In this post hoc analysis of European survey data (Healthcare
Research Worldwide, London, UK; ‘Once Daily Medication Taking
Behaviour Research’ study), we assessed measures of adherence,
perceptual barriers to asthma medication adherence (doubts
about necessity and concerns about adverse effects) and practical
barriers to treatment (the intrusiveness of asthma treatment),
asthma control and healthcare seeking. Preferences for once-daily
vs. twice-daily asthma maintenance medication were also
investigated.
We hypothesised that non-adherence and preferences for
switching to a ‘once-daily medication that works as well as my
current medication’ or a ‘twice-daily medication that works slightly
better than my current medication’ would be predicted by
perceptual and practical factors associated with current treatment,
and that non-adherence would predict healthcare-seeking beha-
viour. Complex pathways may exist between the variables that
impact adherence and treatment frequency preferences; for
example, people with a high perception of treatment need are
likely to be more adherent and so less likely to seek healthcare as
a result of uncontrolled asthma, or may engage more with their
healthcare in general and so be more likely to seek healthcare. To
explore the relationships between these variables, we used
structural equation modelling.
RESULTS
Participant characteristics
Overall, 1010 people with asthma were included in these analyses,
and their demographic and clinical characteristics are presented in
Table 1. The mean age was 36.6 years (standard deviation [SD]
10.2; range 18–55 years), and the median duration of asthma was
15 years (interquartile range [IQR] 7–23 years). Participants had
experienced a median of two asthma attacks in their lifetime (IQR
0–3) and were taking a median of two asthma maintenance
medications (IQR 1–3) (Table 1; full list in Supplementary Table S1).
Asthma medication regimens corresponding to Step 3 of the
global stepwise treatment framework5 were taken by 45.6% of
participants, while 37.6% of participants were taking asthma
medication regimens that corresponded to Step 2 of the
framework, together accounting for 83.3% of all participants
(Table 1).
The mean Asthma Control Test™ (ACT) score was 16.02 (SD
4.17). The majority of participants (76.8%, n = 776) had ACT scores
<19, indicating potential problems with asthma control, and
46.1% of participants (n = 466) had scores <16, indicating poorly
controlled or uncontrolled asthma. Only 1.8% of participants (n =
18) had ‘ideal’ asthma control, with an ACT score of 25.
There was a wide variety of healthcare-seeking frequencies
among participants in the 12 months prior to the survey, with a
median of three general practitioner consultations (range 0–60,
sought by 87.8% of participants, n = 887) and one specialist
consultation (range 0–45, sought by 55.1% of participants, n =
557); two-thirds of participants did not consult a community nurse
(range 0–50, n = 336) (Table 1).
Participant scores and preferences
Participants’ adherence to their asthma maintenance medication
was assessed using the Medication Adherence Report Scale
(MARS). The median MARS score was 3.40 (IRQ 2.90–4.10). When
MARS scores were dichotomised at approximately the lowest third
of scores (<3), 72.4% (n = 731) of participants had MARS scores
indicating high adherence, and 27.6% (n = 279) had scores
indicating low adherence.
Perceived intrusiveness of participants’ maintenance asthma
treatment was investigated using the Asthma Treatment Intru-
siveness Questionnaire (ATIQ). Most participants had ATIQ scores
indicative of low intrusion into their daily lives from their asthma
maintenance medication, and the overall median ATIQ score was
26.00 (IQR 16.00–39.00; of a potential range 13.00–65.00) (Table 2).
Participants’ concerns and beliefs about the necessity of their
asthma medication were collected using the necessity and
concerns subscales of the BMQ. The overall median score was
3.60 for BMQ Necessity (IQR 3.00–4.00) and 2.67 for BMQ Concerns
(IQR 2.00–3.22) (Table 2). The majority of participants (82.5%, n =
833) were broadly convinced of the necessity of maintenance
treatment, with only 17.5% (n = 177) expressing strong doubts
about personal need (BMQ Necessity scores; dichotomised at the
midpoint). However, almost a third of participants had strong
concerns about their current treatment (32.2% [n = 3 25] with high
BMQ Concerns scores; dichotomised at the midpoint). When the
BMQ Necessity and Concerns scores were combined in an
attitudinal analysis, just over half of the participants were classed
as ‘accepting’ of their condition (52.6%, n = 531), approximately a
third of participants were ‘ambivalent’ (29.9%, n = 302) and fewer
participants were ‘indifferent’ or ‘sceptical’ (15.2%, n = 154, and
2.3%, n = 23, respectively) (Fig. 1).
The majority of participants (73.5%, n = 742) expressed a
preference for a ‘once-daily medication that works as well as my
current medication’ rather than a ‘twice-daily medication that
works slightly better than my current medication’. The opposite
preference, favouring the better twice-daily medication, was
expressed by 26.5% of participants (n = 268). The reasons behind
these preferences were not elicited directly, but factors associated
with preferences for once-daily or twice-daily medications were
further explored, as described below.
Signiﬁcant univariate associations
Associations between participant scores are shown in Tables 3 and
4, and select associations are detailed below.
Asthma control correlated positively with reported adherence
levels, duration of asthma and the number of required asthma
medications, and correlated negatively with the numbers of
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lifetime severe asthma attacks and healthcare professional (HCP)
consultations in the prior year (Table 3).
High levels of treatment adherence were positively correlated
with age and negatively correlated with the numbers of severe
lifetime asthma attacks, required asthma medications and HCP
consultations in the prior year (Table 3). Participants preferring
twice-daily asthma medication had higher treatment adherence
levels than participants preferring once-daily medication (Table 4).
Participants preferring once-daily medication were taking fewer
asthma medications than those with a preference for twice-daily
medication (test statistic = 2.418, P = 0.016).
Perceived Treatment Intrusiveness levels correlated negatively
with asthma control, duration and adherence, and correlated
positively with the number of lifetime asthma attacks and required
asthma medications (Table 3). Participants who were female,
had mild asthma or preferred twice-daily asthma medication had
lower ATIQ scores than participants who were male, had
moderate/severe asthma or preferred once-daily asthma medica-
tion (Table 4).
Treatment Necessity scores were negatively correlated with
asthma control and positively correlated with asthma
duration, the number of lifetime asthma attacks and required
asthma medications (Table 3). Participants who had severe
asthma or preferred twice-daily asthma medication had higher
levels of perceived treatment necessity than those with mild/
Table 1. Participant characteristics and clinical factor
Participants N= 1010
Demographic
characteristic
n (%)
Countrya Germany 200 (19.8)
UK 204 (20.2)
Spain 201 (19.9)
France 206 (20.4)
Italy 199 (19.7)
Gender Male 499 (49.4)
Female 511 (50.6)
Marital status Married/cohabiting/
living with partner
655 (64.9)
Single 284 (28.1)
Separated/divorced/
widowed
71 (7.0)
Area of residence Urban 509 (50.4)
Rural 501 (49.6)
Employment Employed, full time 559 (55.3)
Employed, part time 98 (9.7)
Self-employed 97 (9.6)
Unemployed 81 (8.0)
Student 71 (7.0)
Home maker 59 (5.8)
Other 45 (4.5)
Asthma characteristics Median (IQR)
Age at asthma
diagnosis
18.00
(10.00–30.00)
Years since asthma
diagnosis
15.00
(7.00–23.00)
Number of lifetime
asthma attacks
2.00
(0.00–3.00)
Clinical characteristics n (%)
Smoking history I’ve never smoked 451 (44.7)
I did smoke, but don’t
smoke now
274 (27.1)
I only smoke at social
occasions
65 (6.4)
I smoke less than 5
cigarettes a day on
average
52 (5.1)
I smoke 5–15 cigarettes
a day on average
107 (10.6)
I smoke over 15
cigarettes a day on
average
61 (6.0)
Severityb Mild 139 (13.8)
Moderate 694 (68.7)
Severe 117 (11.6)
Not disclosed 60 (5.9)
Medication regimen
stepc
Step 1 94 (9.3)
Step 2 380 (37.6)
Step 3 461 (45.6)
Step 4 32 (3.2)
Step 5 43 (4.3)
Healthcare service use
in relation to asthma
in the prior year
n (%) Median
(IQR)
Table 1 continued
Participants N= 1010
Demographic
characteristic
n (%)
Consultations GP 887 (87.8) 3 (1–5)
Practice/community
nurse
336 (33.3) 0 (0–1)
Specialist/consultant 557 (55.1) 1 (0–2)
Specialist nurse 207 (20.5) 0 (0–0)
Dietician 150 (14.9) 0 (0–0)
Other HCP 153 (15.1) 0 (0–0)
All consultations 964 (95.4) 5 (2–10)
Emergencies Emergency GP
appointments
499 (49.4) 0 (0–1)
Emergency service uses 361 (35.7) 0 (0–1)
Overnight hospital stays
following emergency
care
204 (20.2) 0 (0–0)
Taken to hospital by
ambulance
166 (16.4) 0 (0–0)
Sent to hospital by GP/
specialist
243 (24.1) 0 (0–0)
Hospitalisations 332 (32.9) 0 (0–1)
Total days spent
hospitalised
N/A 2 (1–5)
GP, general practitioner, HCP healthcare professional, IQR interquartile
range, N/A not available
a Country of recruitment
b
“How has your doctor described your asthma?”
c Stepwise treatment framework (GINA, 2015, summary of medication at
each regimen step: step 1, SABAs alone or in combination with allergy
treatment; step 2, ICS alone or leukotriene modiﬁers or ICS in combination
with SABAs or allergy-induced asthma treatment; step 3, LABAs in
combination with ICS or theophylline/related compounds or ICS in
combination with allergy-induced asthma treatment; step 4, ICS in
combination with LABAs and allergy-induced asthma treatment; step 5,
omalizumab)
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moderate asthma or preferred once-daily asthma medication
(Table 4).
Treatment Concerns scores correlated negatively with asthma
control, adherence and asthma duration, and correlated positively
with the numbers of lifetime asthma attacks and required asthma
medications (Table 3). Participants who were female, with mild
asthma, or preferred twice-daily asthma medication had reduced
concerns about treatment vs. participants who were male, had
moderate asthma or preferred once-daily asthma medication
(Table 4).
The MARS adherence scores for participants who preferred
once-daily and twice-daily asthma medication were 3.40 (IQR
2.90–4.00) and 3.60 (IQR 3.00–4.20), respectively. Participants
preferring once-daily asthma medication had lower perceived
treatment necessity, more concerns about treatment and higher
perceived treatment intrusiveness than participants who preferred
twice-daily asthma medication (Table 4).
Structural equation modelling
Structural equation modelling (a statistical technique allowing
multiple causal relationships to be speciﬁed simultaneously, for
outcomes to act as both predictors and outcomes simultaneously
and for measurement error to be included in the models)31 was
Table 2. Participant scores for perceived treatment necessity, concerns about treatment and treatment intrusiveness
Median (IQR)
N= 1010 BMQ necessity scorea
(potential range: 1–5)
BMQ concerns scorea
(potential range: 1–5)
BMQ necessity-
concernsb differential
score
ATIQ total scorec
(potential range: 13–65)
Gender Female 3.60 (3.00–4.00) 2.44 (2.00–3.11) 0.80 (0.13–1.69) 23.00 (14.00–36.00)
Male 3.40 (3.00–4.00) 2.89 (2.22–3.44) 0.38 (0.00–1.09) 33.00 (20.00–39.00)
Countryd Germany 3.60 (3.00–4.00) 2.56 (1.89–3.11) 0.69 (0.04–1.64) 25.50 (15.50–38.00)
UK 3.60 (3.00–4.00) 2.39 (1.89–3.00) 0.91 (0.21–1.61) 19.50 (14.00–37.50)
Spain 3.60 (3.00–4.00) 2.89 (2.44–3.44) 0.38 (0.00–0.98) 33.00 (19.00–40.00)
France 3.80 (3.00–4.00) 2.56 (2.00–3.33) 0.66 (0.09–1.78) 25.00 (16.00–38.00)
Italy 3.40 (2.00–4.00) 3.00 (2.22–3.56) 0.31 (0.00–1.07) 32.00 (19.00–40.00)
Marital status Married/cohabiting/
living with partner
3.60 (3.00–4.00) 2.67 (2.00–3.22) 0.49 (0.00–1.33) 26.00 (15.00–38.00)
Other 3.40 (3.00–4.00) 2.78 (2.22–3.22) 0.62 (0.07–1.47) 29.00 (19.00–39.00)
Area of residence Urban 3.60 (3.00–4.00) 2.78 (2.11–3.33) 0.44 (0.00–1.33) 28.00 (17.00–39.00)
Rural 3.60 (3.00–4.00) 2.56 (2.00–3.11) 0.69 (0.09–1.60) 26.00 (15.00–38.00)
Employment Full-time employment 3.60 (3.00–4.00) 2.78 (2.11–3.33) 0.49 (0.00–1.40) 30.00 (16.00–39.00)
Other employment 3.60 (3.00–4.00) 2.56 (2.00–3.11) 0.64 (0.04–1.51) 25.00 (16.00–37.00)
Asthma severitye Mild 3.20 (2.60–4.00) 2.44 (1.78–3.11) 0.47 (0.00–1.36) 19.00 (13.00–36.00)
Moderate 3.60 (3.00–4.00) 2.89 (2.22–3.33) 0.51 (0.00–1.33) 30.00 (17.00–39.00)
Severe 4.00 (3.40–4.40) 2.67 (2.00–3.33) 1.16 (0.18–2.11) 31.00 (18.00–39.00)
Medication regimen
stepf
Step 1 3.40 (3.00–4.00) 2.83 (2.22–3.33) 0.49 (0.00–1.16) 33.00 (20.00–40.00)
Step 2 3.40 (3.00–3.80) 2.67 (2.00–3.11) 0.51 (0.00–1.27) 27.00 (16.00–39.00)
Step 3 3.60 (3.00–4.00) 2.67 (2.00–3.11) 0.69 (0.09–1.67) 24.00 (15.00–37.00)
Step 4 4.00 (3.40–4.20) 3.22 (2.06–4.00) 0.50 (−0.01–1.30) 36.50 (18.00–43.00)
Step 5 3.60 (3.00–4.00) 3.11 (2.67–3.67) 0.11 (0.00–0.73) 38.00 (30.00–41.00)
Smoking Current smoker 3.60 (3.00–4.00) 2.56 (2.00–3.11) 0.71 (0.07–1.64) 24.00 (14.00–38.00)
Not current smoker 3.60 (3.00–4.00) 2.78 (2.11–3.33) 0.53 (0.00–1.36) 28.00 (17.00–39.00)
Current asthma
medication
Overall score 3.60 (3.00–4.00) 2.67 (2.00–3.22) 0.58 (0.00–1.42) 26.00 (16.00–39.00)
Preference for
treatment
Once-daily asthma
medication
3.40 (3.00–4.00) 2.78 (2.11–3.44) 0.42 (0.00–1.24) 28.00 (16.00–39.00)
Twice-daily asthma
medication
3.80 (3.20–4.00) 2.44 (1.89–3.00) 1.01 (0.34–1.83) 24.00 (15.00–36.00)
ATIQ Asthma Treatment Intrusiveness Questionnaire, BMQ Beliefs about Medicines Questionnaire, ICS inhaled corticosteroid, IQR interquartile range, LABA long-
acting beta2 agonist, SABA short-acting beta2 agonist
a Rated on a 5-point Likert scale (from ‘strongly disagree’= 1 to ‘strongly agree’= 5)
b BMQ Concerns score subtracted from BMQ Necessity score
c Sum of 13 possible intrusions of asthma on participants’ daily lives, each rated on a 5-point Likert-type scale (from ‘low’= 1 to ‘high’= 5
d Country of recruitment
e
“How has your doctor described your asthma?”
f Stepwise treatment framework (GINA, 2015, summary of medication at each regimen step: step 1, SABAs alone or in combination with allergy treatment; step
2, ICS alone or leukotriene modiﬁers or ICS in combination with SABAs or allergy-induced asthma treatment; step 3, LABAs in combination with ICS or
theophylline/related compounds or ICS in combination with allergy-induced asthma treatment; step 4, ICS in combination with LABAs and allergy-induced
asthma treatment; step 5, omalizumab)
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used to test a theoretical, empirical model of associations between
adherence, reported asthma control, healthcare seeking, prefer-
ences for once-daily vs. twice-daily maintenance asthma treat-
ment, beliefs about inhaled corticosteroids and practical barriers
to taking medication (asthma treatment intrusiveness). Two outlier
cases that demonstrated very large deviations from multivariate
normality (Mahalanobis distances >170) were removed. To
produce the most parsimonious model, non-signiﬁcant relation-
ships between latent variables were systematically removed from
the modelling output, and direct paths were added to improve
the model ﬁt. Two models best represented the data (Fig. 1;
Supplementary Fig. S1), which are described below. All pathways
in the ﬁnal models were signiﬁcant at P < 0.01 after bootstrapping
to adjust for bias arising from non-normal distributions.
The ﬁrst model identiﬁed predictors of adherence, healthcare
seeking and asthma control (Fig. 1a; Supplementary Fig. S1a).
Goodness-of-ﬁt statistics indicated that the data deviated
signiﬁcantly from model predictions (Supplementary Table S2),
and the full model deviated signiﬁcantly from a perfect ﬁt (χ2 =
15726.58 [degrees of freedom = 1243], P < 0.001). Complex inter-
relationships were indicated, which included an association
between higher levels of concern about treatment and increased
perceptions of treatment intrusiveness and reduced adherence,
which in turn inﬂuenced asthma control. Perceived necessity of
treatment, concerns about treatment and treatment intrusiveness
inﬂuenced each other, adherence and asthma control. Asthma
severity and adherence negatively impact on healthcare-seeking
behaviour, while asthma control had a positive impact on
healthcare-seeking behaviour. The proportion of variance in
individual dependent variables indicated that the model predicted
36.1% of variance in self-reported adherence on the MARS scale,
and 32.0% of variance in asthma control. However, only 4.4% of
variance in healthcare-seeking was explained by the model.
The second model identiﬁed predictors of preference for once-
daily vs. twice-daily treatment (Fig. 1b; Supplementary Fig. S1b).
Goodness-of-ﬁt statistics indicated that the data deviated
signiﬁcantly from model predictions (Supplementary Table S3),
and the full model deviated signiﬁcantly from a perfect ﬁt (χ2 =
6029.50 [degrees of freedom = 420], P < 0.001). Several factors
were identiﬁed that inﬂuence preferences for once-daily or twice-
daily medication: concerns about treatment, mild asthma severity,
country of origin (UK, Italy or Germany), high cholesterol levels,
full-time employment, higher number of medications taken, high
ACT score and high levels of healthcare-seeking behaviour. The
strongest predictors of preference for twice-daily asthma medica-
tion were concerns about treatment and healthcare-seeking
behaviour. The included variables accounted for 21.2% of variance
in preference for once-daily vs. twice-daily asthma medication.
Participants who reported higher concerns and higher healthcare
seeking tended to prefer twice-daily to once-daily asthma
medication. (Fig. 2)
DISCUSSION
Main ﬁndings
This post hoc analysis used survey data from people with asthma
across ﬁve European countries to gain insight into adherence,
asthma control, perceived treatment intrusiveness, healthcare-
seeking behaviour and preferences for once-daily vs. twice-daily
asthma medication. Although most participants reported good
adherence to prescribed medication, the median MARS score of
3.40 (of a possible 5.00 for perfect adherence) suggested poor
adherence by many patients; however, there was considerable
variation in the data. The study identiﬁed variations in beliefs
about treatment (necessity and concerns) and subjective treat-
ment burden (Perceived Treatment Intrusiveness), and these
perceptions were related to non-adherence as anticipated. The
majority of participants (73.5%, n = 742) expressed a preference
for a ‘once-daily medication that works as well as my current
medication’, compared with a ‘twice-daily medication that works
slightly better than my current medication’.
Structural equation modelling identiﬁed complex inter-
relationships between beliefs about medication, and treatment
intrusiveness and adherence factors: positive beliefs about
treatment (high necessity, low concerns) and higher adherence
levels positively inﬂuenced asthma control, leading to less
healthcare-seeking behaviour, whereas barriers to adherence
and asthma severity had the opposite effect. In the ﬁrst model,
higher levels of concern about treatment were associated with
increased perceptions of treatment intrusiveness and reduced
adherence, which in turn inﬂuenced asthma control. The second
model identiﬁed that higher levels of concern about treatment
and healthcare-seeking behaviour were also predictive of
preference for twice-daily asthma medication. The full models
deviated signiﬁcantly from perfect ﬁt, as would be expected due
to the difﬁculty of ﬁtting complex models of human behaviours
and beliefs precisely, and the high power to detect deviation from
the model due to the large sample size. The model directly
predicted approximately a third of the variance in adherence and
asthma control, but only predicted a small proportion of the
variance in healthcare seeking, indicating that further variables
may be relevant for this. In general, structural equation modelling
identiﬁed a wide variety of factors that were associated with a
preference for once-daily asthma maintenance medication among
participants.
Interpretation of ﬁndings in relation to previously published work
The number of participants reporting a preference for once-daily
treatment in this study was greater than that in other surveys of
patients with asthma.30 We do not know the reason for this but it
may be linked to the fact that, in this survey, the once-daily
medication was described as being as effective as participants’
current medication. This description was not included in other
surveys and may have led those participants to assume that a
reduced frequency was associated with reduced efﬁcacy of the
medication. In our study, two key factors emerged as predictors of
preference for more effective twice-daily asthma medication over
once-daily asthma medication: high levels of treatment concerns
and high levels of healthcare seeking. Participants who were more
worried about their asthma medication, and were seeking more
healthcare support, appeared to want more effective twice-daily
asthma treatments in preference to once-daily dosing with a
medication that would be as effective as their current treatment.
Despite healthcare seeking being the strongest predictor of twice-
daily asthma treatment preference in the structural equation
model, there were no signiﬁcant univariate associations between
Fig. 1 BMQ attitudinal analysis. BMQ, Beliefs about Medicines
Questionnaire
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healthcare seeking and preference. The structural equation model
may have been more able to detect an effect of healthcare
seeking, whereas univariate analyses were performed for indivi-
dual healthcare-seeking behaviours (including being hospitalised,
calling an ambulance and staying overnight in hospital), which
contributed to a single, composite latent variable in the structural
equation model. Additionally, in the multivariate analysis, the
effect of healthcare seeking may have become more important
when other variables, which may interact or be confounded with
healthcare seeking, were held constant.
In our study, relationships between asthma control, adherence
to asthma medication, perceptual and practical barriers to
adherence, and healthcare seeking largely conformed to predic-
tions of the PAPA model and the NCF.16 Well-controlled asthma
was associated with reduced healthcare seeking and increased
adherence, compared with poorly controlled asthma, as previously
reported.32 A separate study has previously found that, as
expected, participants with a higher perceived need for their
asthma maintenance treatment reported higher adherence to
asthma medication, and participants who reported concerns
about the potential adverse effects of their asthma medication or
found their asthma medication intrusive were typically less
adherent. Patients who perceive asthma to have potentially
severe consequences and feel involved in their treatment
decisions are known to be more likely to adhere to treatment.33
A recent study showed that negative beliefs about medication
associated with non-adherence may not be addressed in asthma
consultations with specialist nurses.25 Other studies have demon-
strated interventions that appear to enhance necessity beliefs,
reduce concerns and improve adherence.34,35
Strengths and limitations of this study
The strengths of our analysis include the large number of
participants (N = 1010), the collection of data in ﬁve European
countries and the use of validated scales for adherence,17,36 asthma
control,37 beliefs about medications17 and perceived treatment
intrusiveness.38 A limitation of the study was that an existing cross-
sectional observational study dataset was used (collected in 2011),
which meant that causal and temporal relationships could not be
ascertained. Also, the surveyed individuals may be unrepresentative
of the whole population of patients with asthma as participants
received ﬁnancial incentives for completing the surveys, and
information on socioeconomic status was not gathered. Other
limitations were the use of self-reported illness and healthcare-
seeking data, which may have been subject to reporting bias, and
that the measures of preference used for once-daily vs. twice-daily
treatment, and asthma severity, were single-item scales and so may
not have produced consistent results.
Implications for future research, policy and practice
Future studies should consider using multiple-item scales to
determine asthma severity and to provide more sophisticated
discrete-choice methodologies to better evaluate patients’ pre-
ferences. In addition, it may be possible to determine more
speciﬁc reasons for non-adherence by measuring the forms of
non-adherence (such as erratic non-adherence, intelligent non-
adherence and unwitting non-adherence) and monitoring the
efﬁciency of inhaler usage.39
Our ﬁndings are the ﬁrst to include measures of practical
barriers in the application of a PAPA model and indicated complex
relationships between adherence and a number of factors. In
particular, barriers to adherence (asthma treatment intrusiveness,
concerns about asthma medication and doubts about the need
for maintenance treatment) appear to have an important impact
on adherence levels. Strong links between adherence and asthma
control were identiﬁed, as was the role that asthma control,
adherence to medication, asthma severity and asthma-treatmentT
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Fig. 2 Simpliﬁed structural equation models identifying a predictors of adherence, healthcare seeking and asthma control, and b predictors
of preference for once-daily vs. twice-daily treatment. ACT, Asthma Control Test™; ATIQ, Asthma Treatment Intrusiveness Questionnaire; BMQ,
Beliefs about Medicines Questionnaire; MARS, Medication Adherence Report Scale. a Simpliﬁed structural equation model of association
between adherence barriers, adherence, healthcare seeking, asthma control and asthma severity. All paths represent standardised regression
weights of latent variables, corrected by bootstrapping, and are signiﬁcant at P = 0.01. Paths with a positive score have a positive impact of the
connected variables, while negative scores indicate negative impacts. b Simpliﬁed structural equation model of predictors of preference for
once-daily vs. twice-daily treatment. All paths represent standardised regression weights of latent variables, corrected by bootstrapping, and
are signiﬁcant at P = 0.01. Positive paths are equivalent to an increased preference for twice-daily medication. Negative paths mean an
increased preference for once-daily medication. ACT, Asthma Control Test™; ATIQ, Asthma Treatment Intrusiveness Questionnaire; BMQ,
Beliefs about Medicines Questionnaire; MARS, Medication Adherence Report Scale
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intrusiveness play in predicting healthcare seeking. Finally, various
barriers to adherence, asthma control, demographic and clinical
factors were associated with preferences for once-daily vs. twice-
daily medication, with increased healthcare seeking and higher
concerns about current treatment leading to a preference for a
twice-daily medication that is more effective than current
treatment. Future studies may use PAPA to assess barriers to
adherence via the three phases of adherence: initiation, imple-
mentation and persistence.6 It would also be interesting to include
exacerbation history in future studies, to identify whether frequent
asthma exacerbations (which may be predicted by high blood
eosinophil counts)40 are predictive of adherence or preferences
for once-daily or twice-daily medication.
CONCLUSIONS
Our ﬁndings conﬁrm the utility of the Perceptions and Practi-
calities Approach (PAPA) and Necessity Concerns Framework
(NCF) in explaining non-adherence linked to poor asthma control.
To understand patient adherence to current medication and
preferences for once-daily vs. twice-daily treatment, it is crucial to
consider the perspectives of the individual patient. Supporting
adherence to treatment requires a dual approach that considers
perceptions (e.g., treatment necessity beliefs and concerns) as well
as the practicalities (e.g., addressing the ability to adhere by
making the regimen easy to use). This might be achieved through
a three-step PAPA approach:15 (1) communicating a ‘common-
sense’ rationale for why the treatment is necessary to achieve
goals that are valued by the patient, (2) eliciting and addressing
patient concerns, and (3) addressing practical barriers, for
example, by simplifying the regimen and/or improving inhaler
technique.
METHODS
Study design
This post hoc analysis was conducted using cross-sectional, web-based
survey data obtained in 2011, from ﬁve European countries (Germany,
Spain, France, Italy and the UK). This market research survey did not
require ethics committee or review board approval.
Participants
Participants were recruited by a recruitment agency (Toluna Proprietary).
The agency actively managed market research panels across all ﬁve target
countries using advertisements in search engines, online banners,
telephone recruitment and mail. The survey was administered online.
Sampling was non-random, targeting a minimum of 200 respondents per
country (100 male and 100 female); quotas were applied to ensure an
approximately similarly sized sample across all ﬁve target countries and
equal numbers of male and female respondents. Financial incentives were
given for participation in the survey. The study methods were explained to
all potential participants before obtaining informed consent. Participants
were also informed that the anonymous data would be used in
publications.
People aged between 18 and 55 years of age, with a self-reported
asthma diagnosis (and able to deﬁne age at asthma diagnosis), who were
taking at least one daily asthma maintenance treatment medication
(zaﬁrlukast, ciclesonide, beclometasone, budesonide, ipratropium bromide,
ﬂuticasone, formoterol plus beclometasone, sodium cromoglicate, salme-
terol plus ﬂuticasone, montelukast, formoterol plus budesonide, nedocro-
mil sodium, omalizumab or salbutamol plus ipratropium), and who
expected to experience asthma symptoms on most days (or every day) if
asthma medication was not taken every day, were eligible to take part in
the survey. People were excluded from the study if they self-reported a
diagnosis of chronic obstructive pulmonary disease (COPD), if they were
aged over 55 years (to exclude patients with COPD) and once gender/
nationality/age quotas had been met.
Measures
Participants were categorised in terms of the highest ‘Step’ of medication
they were taking, based on current global guidelines.5
Medication adherence was measured using the MARS (©Professor Rob
Horne; 10-item version; Supplementary Table S4).36,41
Self-reported preference for once-daily vs. twice-daily asthma main-
tenance (preventer) medication taking was elicited by asking participants
the following: ‘If your doctor gave you a choice of two possible new
preventer medications, which one would you choose?’. The two possible
response options were as follows: ‘once-daily medication that works as
well as my current medication’ and ‘twice-daily medication that works
slightly better than my current medication’.
Self-reported asthma severity was elicited by asking participants
whether their doctor had described their asthma as ‘mild’, ‘moderate’ or
‘severe’. Asthma control was measured by the ACT, as previously
described.37 Self-reported healthcare seeking was elicited by asking
participants how many times in the last year they had consulted HCPs
regarding their asthma or needed to use emergency medical services due
to their asthma (including being hospitalised, calling an ambulance, being
sent to the hospital by their GP/asthma specialist doctor and staying
overnight in hospital), and if they had, how many days their asthma had
led them to be hospitalised in the last year.
To assess the extent to which taking asthma medication interferes with
participants’ daily lives, practical barriers to medication taking were
measured using ATIQ (©Professor Rob Horne), a tool which was adapted for
use in asthma for this study (full details are provided in the Supplementary
Materials).38,42 Participants were asked to indicate, on a ﬁve-point Likert-
type scale (from ‘low’ = 1 to ‘high’ = 5), the degree to which each of 13
possible intrusions of asthma affected their daily lives. To obtain total
scores, the items were summed; the potential range of scores was 13–65.
Participants’ perceived need for treatment was measured using
the’Necessity’ subscale of the BMQ questionnaire,17 referring to partici-
pants’ preventer inhaler (Supplementary Table S4). Concerns about
potential negative effects of treatment were measured using a modiﬁed
‘Concerns’ subscale of the BMQ questionnaire (©Professor Rob Horne),17
which included additional items resulting in a 9-item scale (Supplementary
Table S4). Both scales were rated on 5-point Likert scales from ‘strongly
agree’ to ‘strongly disagree’. For each scale, items were summed and then
divided by the total number of items in the scale to obtain comparable
scores (range 1–5), higher scores indicating stronger agreement with the
scale construct.
All questionnaire scales had good reliability for all participants,
regardless of location (Cronbach’s α scores were as follows: ATIQ = 0.954
[all countries α > 0.94]; MARS = 0.872 [all countries α > 0.850]; BMQ
Concerns = 0.890 [all countries α > 0.86]; and BMQ Necessity = 0.811 [all
countries α > 0.70]). The scales were dichotomised at their midpoint into
high and low groups to describe the data, and then combined to form four
attitudinal groups to describe the pattern of beliefs in the sample as
established previously.43 A difference score (BMQ necessity–concerns
differential; BMQ NCD) was also calculated to describe participants’ implicit
evaluation of overall beneﬁts vs. the risks of treatment.
Analyses
Only complete surveys were analysed. All analyses were conducted using
SPSS 22 (IBM, New York, USA) and the Amos™ structural equation
modelling plug-in (Amos Development Corporation, Florida, USA), with α =
0.05 to test for statistical signiﬁcance. To conﬁrm internal reliability of the
scales, Cronbach’s alpha values were calculated for BMQ Necessity, BMQ
Concerns, ATIQ treatment intrusiveness, ACT and MARS. To enhance
reliability of the BMQ scales, items were removed before calculating total
scores, resulting in a 5-item necessity and 9-item concerns scale drawn
from an initial pool of 23 potential items. Descriptive characteristics of the
entire population on all key variables were summarised (including gender,
age, nationality, employment, BMQ scores, ACT scores, ATIQ scores, MARS
scores and healthcare-seeking reports). A NCD score, representing the
overall evaluation by patients of their asthma medications, was calculated
and used as a predictor in the univariate models. Univariate relationships
were tested for signiﬁcance using Pearson or Spearman statistics, χ2 or F/t-
tests or Mann–Whitney U-tests, dependent on distribution and variable
type (categorical/continuous), between asthma control (as measured by
ACT), reported adherence (as measured by MARS), preference for once-
daily vs. twice-daily treatment, perceptual barriers (BMQ necessity and
concerns scores) and practical barriers (ATIQ score), reported asthma
severity, reported healthcare seeking and clinical and demographic factors.
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Levene’s tests for equality of variances were examined, and degrees of
freedom were adjusted where variances were unequal between groups.
Structural equation modelling of multivariate relationships (including
latent variables, error terms and analyses) was conducted. Maximum
likelihood estimation was used to obtain estimates of model parameters.
Bootstrapping using 500 samples from the original data set was used to
adjust for non-normality in the data and to produce unbiased estimates of
parameters and parameter errors. Mahalanobis distances were examined
to identify outliers. Modiﬁcation indices were used to identify potential
adjustments to the model; only meaningful adjustments were considered
(e.g., correlated errors for unrelated scales were not allowed). Non-
signiﬁcant relationships between latent variables were removed to
produce the most parsimonious model (i.e., the model that included the
fewest assumptions and variables while remaining able to explain the
data). Goodness of ﬁt indices (adjusted goodness of ﬁt index, goodness of
ﬁt index, normed ﬁt index, parsimony goodness of ﬁt index, relative ﬁt
index and root mean square error of approximation) were used to
ascertain the value of the ﬁnal model. The consistency of the proposed
causal structure in the two models was tested across country samples by
conducting the separate structural equation models in each country and
evaluating whether qualitative differences in the magnitude and direction
of the relationships in the models exist. Models which failed to converge or
resulted in positive deﬁnite matrices or squared multiple correlations
greater than one (all indicative of speciﬁcation errors) were excluded.
An exploratory model-building approach44 was used to check data were
available for enough participants to ensure an adequate sample size for
this post hoc analysis with the following assumptions: all of the
determinants of adherence had only a small effect on this outcome when
combined (d = 0.1) and six latent variables were being modelled (i.e.,
perceived treatment need, perceived treatment concerns, treatment
intrusiveness, adherence, asthma control and healthcare seeking) using
30 observed variables (the items comprising the BMQ, ATIQ, MARS, ACT
and healthcare-seeking scales). A minimum sample of 100 participants was
needed to detect the model structure, and 526 participants were needed
to detect the combined effect of the variables on adherence at α = 0.5 and
power of 0.8.
Data availability
Access to the data sets supporting the conclusions of this manuscript may
be obtained via https://www.clinicalstudydatarequest.com/.
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